Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. pediatric
Show results for
Products
Services
Software
Training
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • Older

Pediatric Articles & Analysis

297 news found

Empowering Asthma Care: Bedfont® Scientific Limited Provides Vital Support for FeNO Testing in Response to Updated NICE Asthma Guidelines

Empowering Asthma Care: Bedfont® Scientific Limited Provides Vital Support for FeNO Testing in Response to Updated NICE Asthma Guidelines

Bedfont® Scientific Ltd., world leaders in breath analysis with over 47 years of knowledge in designing and manufacturing medical breath analysis devices, welcomes the recent update to the National Institute for Health and Care Excellence (NICE) guidelines on asthma management. Bedfont® manufactures the NObreath® Fractional exhaled Nitric Oxide (FeNO) device, which aids in diagnosing ...

ByBedfont Scientific Limited


CD Formulation—Provider of Contract Development and Manufacturing Services for Innovative Oral Film Products

CD Formulation—Provider of Contract Development and Manufacturing Services for Innovative Oral Film Products

Oral thin films are remarkably versatile and can be designed to dissolve quickly in the mouth without the need for water, making them especially beneficial for pediatric and geriatric patients or individuals with swallowing difficulties. ...

ByCD Formulation


Needle Fear No More

Needle Fear No More

At best, most of us tolerate needles. Whether a vaccine, an IV drip, or a blood draw, we can talk ourselves through it with the knowledge that it is for the greater good and will only cause temporary discomfort. On the other side of the spectrum, there are people with such an intense fear of needles that they are considered to have a phobia, trypanophobia to be precise. Many articles have been ...

ByMedsource Labs


Biotech Stock News Bite - Longeveron Inc. (NASDAQ: LGVN) Stock Soars on Clinical Pipeline and 2024 Key Priorities and Goals

Biotech Stock News Bite - Longeveron Inc. (NASDAQ: LGVN) Stock Soars on Clinical Pipeline and 2024 Key Priorities and Goals

In 2024, we are focusing our efforts on two of our most promising programs: Hypoplastic Left Heart Syndrome (HLHS); and Alzheimer's Disease. HLHS: HLHS is a rare pediatric disease affecting approximately 1000 live births per year in the US. ...

ByInvestorideas.com


Synaptive’s Modus X Takes Center Stage in the latest issue of the Journal of Neurosurgery’s Neurosurgical Focus on exoscopes in neurosurgery

Synaptive’s Modus X Takes Center Stage in the latest issue of the Journal of Neurosurgery’s Neurosurgical Focus on exoscopes in neurosurgery

January’s Journal of Neurosurgery (JNS) published a series of 17 videos that examine the application of exoscopic visualization in cerebrovascular, neuro-oncologic, pediatric, peripheral nerve, and spinal neurosurgery. The video series highlights the exoscope as a versatile alternative to traditional optical microcopy. ...

BySynaptive Medical


Intermountain Primary Children’s Hospital First in Nation to Successfully Implant New Brain Shunt Accessory for Patients with Hydrocephalus

Intermountain Primary Children’s Hospital First in Nation to Successfully Implant New Brain Shunt Accessory for Patients with Hydrocephalus

U of U Health and Intermountain Primary Children’s Hospital pediatric neurosurgeon, Sam Cheshier, MD, was the first surgeon to implant this new shunt accessory in a patient this summer at Primary Children’s Hospital. ...

ByAnuncia Medical, Inc.


Research on Safe Nebulizer Inhalation Therapy Using Clean Booth and Particle Counters

Research on Safe Nebulizer Inhalation Therapy Using Clean Booth and Particle Counters

It is an important treatment not only for asthma patients, but for otolaryngology and pediatrics in a variety of settings as well. In order to administer safe Nebulizer Inhalation Therapy, a clean booth equipped with Push & Pull fan filter units with HEPA filter was constructed, and the change in particle concentration in a clean booth with different operating conditions of a ...

ByParticles Plus, Inc.


Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension and Quillivant ER Chewable Tablet for the Treatment of Attention Deficit Hyperactivity Disorder

Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension and Quillivant ER Chewable Tablet for the Treatment of Attention Deficit Hyperactivity Disorder

Quillivant ER Oral Suspension allows for personalized dosing with ease of titration and the Quillivant ER chewable tablets are scored tablets, which are ideal for pediatric patients, providing additional flexibility in dose administration with the most dosing options available in an extended-release methylphenidate tablet. ...

ByTris Pharma, Inc.


Anuncia Medical Announces the First Successful US Implant of the Company’s Newly Commercially Released ReFlow Mini Flusher Device for Hydrocephalus Patients

Anuncia Medical Announces the First Successful US Implant of the Company’s Newly Commercially Released ReFlow Mini Flusher Device for Hydrocephalus Patients

In May, a study on the improved outcomes of 9 ReFlow patients was published in Pediatric Neurosurgery. Patients with hydrocephalus often experience repeat brain surgeries because their shunts become occluded with tissue and cells in the CSF within cavities, or ventricles, of the brain. ...

ByAnuncia Medical, Inc.


TOMI Secures Vizient Contract as an Approved Supplier of SteraMist Systems for Nationwide Healthcare Networks

TOMI Secures Vizient Contract as an Approved Supplier of SteraMist Systems for Nationwide Healthcare Networks

This contract enables TOMI to supply SteraMist systems to a wide range of healthcare providers, including academic medical centers, pediatric facilities, and community health providers, through Vizient's nationwide network. ...

BySteraMist Disinfection


Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting

Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting

Key presentations on Bayer research to be presented at AACR 2023 are listed below: Oral presentation: BAY 2965501: A highly selective DGKzeta inhibitor for cancer immuno-therapy with first-in-class potential Abstract ND04, Session DDT001 – New Drugs on the Horizon: Part 1 Sunday, April 16, 2:05 PM – 2:20 PM (EDT), Tangerine Ballroom 2 (WF2) - Convention Center Poster ...

ByBayer AG


Ony Biotech Prepares For The Future

Ony Biotech Prepares For The Future

Cummings, who earned his medical degree and completed his residency at the State University of New York’s Upstate Medical Center in Syracuse, New York, served as a Professor of Pediatrics and Bioethics at Albany Medical Center in the Capital Region. ...

ByONY Biotech


Roswell Biotechnologies Forms Scientific Advisory Board

Roswell Biotechnologies Forms Scientific Advisory Board

Nelson is Professor of Human Genetics, Psychiatry, Pediatrics, Pathology and Laboratory Medicine in the David Geffin School of Medicine at the University of California, Los Angeles. ...

ByRoswell Biotechnologies Inc


Ultravist by Bayer now approved for contrast-enhanced mammography in EU

Ultravist by Bayer now approved for contrast-enhanced mammography in EU

Depending on the country, Ultravist is approved for use across a vast range of indications such as CT of the head, chest, heart, abdomen, and liver; multi-detector CT for stroke/ischemic damage and imaging of the abdominal viscera; CT angiography of vessels in the head, heart and peripheral parts of the body; conventional radiology for duct systems/body cavities and urography; contrast ...

ByBayer AG


Eagle Pharmaceuticals Provides Business Update and Guidance for 2023

Eagle Pharmaceuticals Provides Business Update and Guidance for 2023

Commercial and Pipeline Update Product portfolio Acute Care Hospital: RYANODEX®, vasopressin, Barhemsys®, Byfavo® Oncology: BENDEKA, BELRAPZO, PEMFEXY11, TREAKISYM Japan12 75-person commercial team covers all products excluding BENDEKA and TREAKISYM Company projects growth in earnings while still supporting R&D Cash flow from legacy products expected to continue to ...

ByEagle Pharmaceuticals, Inc.


Combines mesenchymal stem-cell-based product, with Kurve’s intranasal drug delivery technology

Combines mesenchymal stem-cell-based product, with Kurve’s intranasal drug delivery technology

About Hospital Infantil Universitario Niño Jesús Niño Jesús University Children’s Hospital, birthplace of pediatrics in Spain, has been a national benchmark in pediatric healthcare since it was founded in 1877. ...

ByKurve Therapeutics, Inc.


Third Pole Therapeutics Receives $32M Strategic Equity Investment to Accelerate its Tankless Inhaled Nitric Oxide (iNO) Platform

Third Pole Therapeutics Receives $32M Strategic Equity Investment to Accelerate its Tankless Inhaled Nitric Oxide (iNO) Platform

Since then, in addition to blue babies, hundreds of thousands of pediatric and adult patients experiencing elevated pulmonary pressure, inflammation and poor oxygenation during and after heart surgery have been treated with inhaled nitric oxide, creating a $600 million inhaled nitric oxide market, concentrated in large hospitals, and developed markets. ...

ByThird Pole Therapeutics, Inc.


Osso VR Expands Leadership Team with Two New Hires

Osso VR Expands Leadership Team with Two New Hires

Led by UCLA and Harvard trained pediatric orthopedic surgeon Justin Barad, MD, Osso VR’s platform covers multiple surgical specialties and is available in over 20 ...

ByOsso VR, Inc.


Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, and a PK/PD trial, the OraGrowtH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to ...

ByLumos Pharma


Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD

Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD

(NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on rare endocrine disorders, announced that the Company will host two key opinion leaders in the field of pediatric endocrinology for a discussion of interim data from our Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials evaluating oral LUM-201 in Pediatric Growth Hormone Deficiency (PGHD). ...

ByLumos Pharma

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT